Ertugliflozin
Back to searchMolecule Structure
Scientific Name
Ertugliflozin
Description of the Drug
Ertugliflozin is a SGLT2 inhibitor used to treat type 2 diabetes mellitus.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11827
http://www.drugbank.ca/drugs/DB11827
Brand Name(s)
Steglatro
Company Owner(s)
Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL3884 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL181047 | |
| PharmGKB | PA166269521 | |
| DrugBank | DB11827 | |
| PubChem: Thomson Pharma | 89442948 | |
| PubChem | 44814423 | |
| Nikkaji | J2.857.519J | |
| BindingDB | 50342885 | |
| EPA CompTox Dashboard | DTXSID40153120 | |
| DrugCentral | 5270 | |
| ChemicalBook | CB22583105 | |
| Guide to Pharmacology | 8376 | |
| rxnorm | STEGLATRO | ERTUGLIFLOZIN |
| ChEBI | 188719 | |
| ZINC | ZINC000068197809 |
